Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Pharma Holdings, a specialty biopharmaceutical company, has announced that its novel antibiotic combination formula has received approval from the China's State Food and Drug Administration to enter clinical trials.
Subscribe to our email newsletter
The company will initiate clinical trials in November 2008 to evaluate this drug, a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor, for the treatment of infections.
Zhilin Li, CEO and president of China Pharma, said: “We are pleased that the State Food and Drug Administration has approved our new antibiotic formula to enter clinical trials within our anticipated timeframe.
“We look forward to initiating and completing these clinical trials over the next two years and hope to confirm previous results that showed significant efficacy in clearing antibiotic resistant bacterial strains.”